| |
| |
|
| Insider
Information: |
Studer Jacqueline |
| Relationship: |
|
| City: |
Chicago |
| State: |
IL |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
518,821 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$8,957,136 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
518,821 |
|
|
| Total
Value |
$8,957,136 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Allscripts Healthcare Solutions ... |
MDRX |
Sr. VP and General Cou... |
2012-08-31 |
101,102 |
2011-08-31 |
0 |
Premium* |
|
|
Idexx Laboratories Inc |
IDXX |
CVP, Gen. Counsel & Se... |
2019-02-26 |
4,389 |
2015-09-01 |
0 |
Premium* |
|
|
Akili Ord Shs |
AKLI |
|
2024-05-02 |
413,330 |
2022-11-02 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
42 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| IDXX |
Idexx Laboratories Inc |
CVP, Gen. Counsel & Secretary |
• – – |
2018-08-21 |
4 |
S |
$243.36 |
$2,835,375 |
D/D |
(11,619) |
7,634 |
0 |
- |
|
| IDXX |
Idexx Laboratories Inc |
CVP, Gen. Counsel & Secretary |
• – – |
2018-08-31 |
4 |
D |
$254.04 |
$133,117 |
D/D |
(524) |
8,239 |
0 |
- |
|
| IDXX |
Idexx Laboratories Inc |
CVP, Gen. Counsel & Secretary |
• – – |
2018-08-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,129 |
8,763 |
0 |
- |
|
| IDXX |
Idexx Laboratories Inc |
CVP, Gen. Counsel & Secretary |
• – – |
2018-08-06 |
4 |
OE |
$79.54 |
$683,885 |
D/D |
8,598 |
14,447 |
0 |
- |
|
| IDXX |
Idexx Laboratories Inc |
CVP, Gen. Counsel & Secretary |
• – – |
2018-08-21 |
4 |
OE |
$67.85 |
$952,000 |
D/D |
11,619 |
19,253 |
0 |
- |
|
| MDRX |
Allscripts Healthcare Sol... |
EVP and General Counsel |
• – – |
2011-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
30,624 |
30,624 |
0 |
- |
|
| MDRX |
Allscripts Healthcare Sol... |
Sr. VP and General Counsel |
• – – |
2012-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,094 |
80,718 |
0 |
- |
|
| MDRX |
Allscripts Healthcare Sol... |
Sr. VP and General Counsel |
• – – |
2012-08-31 |
4 |
D |
$10.50 |
$25,263 |
D/D |
(2,406) |
101,102 |
0 |
- |
|
| MDRX |
Allscripts Healthcare Sol... |
Sr. VP and General Counsel |
• – – |
2012-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
22,790 |
103,508 |
0 |
- |
|
| AKLI |
Akili Ord Shs |
Chief Legal Officer |
• – – |
2022-11-02 |
4 |
A |
$0.00 |
$0 |
D/D |
322,262 |
322,262 |
0 |
- |
|
| AKLI |
Akili Ord Shs |
Chief Legal Officer |
• – – |
2023-11-02 |
4 |
D |
$0.39 |
$721 |
D/D |
(1,840) |
346,452 |
0 |
- |
|
| AKLI |
Akili Ord Shs |
Chief Legal Officer |
• – – |
2023-09-11 |
4 |
S |
$1.05 |
$1,187 |
D/D |
(1,130) |
348,292 |
0 |
- |
|
| AKLI |
Akili Ord Shs |
Chief Legal Officer |
• – – |
2023-05-02 |
4 |
D |
$1.09 |
$2,006 |
D/D |
(1,840) |
349,422 |
0 |
- |
|
| AKLI |
Akili Ord Shs |
Chief Legal Officer |
• – – |
2023-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
29,000 |
351,262 |
0 |
- |
|
| AKLI |
Akili Ord Shs |
Chief Legal Officer |
• – – |
2024-05-02 |
4 |
D |
$0.41 |
$752 |
D/D |
(1,840) |
413,330 |
0 |
- |
|
| AKLI |
Akili Ord Shs |
Chief Legal Officer |
• – – |
2024-03-10 |
4 |
D |
$0.34 |
$351 |
D/D |
(1,032) |
415,170 |
0 |
- |
|
| AKLI |
Akili Ord Shs |
Chief Legal Officer |
• – – |
2023-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
69,750 |
416,202 |
0 |
- |
|
42 Records found
|
|
Page 2 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
